Somewhat Positive Press Coverage Somewhat Unlikely to Affect Covidien (COV) Share Price
News coverage about Covidien (NYSE:COV) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Covidien earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the healthcare company an impact score of 46.1996335616371 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Covidien (NYSE:COV) opened at $106.71 on Monday. Covidien has a fifty-two week low of $65.97 and a fifty-two week high of $108.57. The company has a market cap of $48,980.00, a price-to-earnings ratio of 27.43 and a beta of 1.01.
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.
Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with MarketBeat.com's FREE daily email newsletter.